Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ab1fb5506fe4ad2bab444f7e8aa63d5a http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_dfd01544a9b2931ae581f1c784a17f6e http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ed28726de9f916f355f8adc331e736b8 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1825 |
classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-50 |
filingDate |
2014-02-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
2017-01-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_993ad0f267bb754376a1302e539c3b39 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f808347ffef9888da7fce8a0ea7d1707 |
publicationDate |
2017-01-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-9550820-B2 |
titleOfInvention |
Chimeric fibroblast growth factor 23/fibroblast growth factor 19 proteins and methods of use |
abstract |
The present invention relates to an isolated chimeric protein. The isolated chimeric protein includes an N-terminus coupled to a C-terminus, where the N-terminus includes an N-terminal portion from a fibroblast growth factor (“FGF”) 23 molecule and the C-terminus includes a C-terminal portion from an FGF19 molecule. The present invention also relates to a pharmaceutical composition including an isolated chimeric protein and a pharmaceutically acceptable carrier. The isolated chimeric protein includes an N-terminus coupled to a C-terminus, where the N-terminus includes an N-terminal portion from a fibroblast growth factor (“FGF”) 23 molecule and the C-terminus includes a C-terminal portion from an FGF19 molecule, and a pharmaceutically-acceptable carrier. Yet another aspect of the present invention relates to a method for treating a subject suffering from a disorder. This method includes selecting a subject suffering from the disorder and administering to the subject a therapeutically effective amount of a chimeric protein according to the present invention. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10464979-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10174090-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11370841-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10189883-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10377806-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11564972-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10758590-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10703788-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10633424-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11141460-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11066454-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11065302-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11103554-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9926355-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9926356-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10744185-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10364278-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11248031-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11241481-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9907830-B2 |
priorityDate |
2013-02-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |